Company: NMP
Filing Date: 2025-02-10
Form Type: DRS
Source: 0001213900-25-011477
Chunk: 90

Company: NMP Acquisition Corp.
Filing Date: 2025-02-10
Form: DRS
Chunk 90
---
 expected when the ordinary shares owned by our sponsor, holders of our private placement units or holders of our working capital loans, if applicable, or their respective permitted transferees are registered. Our sponsor paid an aggregate of $25,000, or approximately $0.0065 per founder share, and, accordingly, you will experience immediate and substantial dilution upon the purchase of our ordinary shares. The difference between the public offering price per share (allocating all of the unit purchase price to the Class A ordinary shares and none to the rights included in the units) and the pro forma net tangible book value per Class A ordinary share after this offering constitutes the dilution to you and the other investors in this offering. Our sponsor acquired the founder shares at a nominal price, significantly contributing to this dilution. Upon the closing of this offering, you and the other public shareholders will incur an immediate and substantial dilution of approximately [__]% (or $[__] per share, assuming no exercise of the underwriters’ over -allotmentoption), the difference between the pro forma net tangible book value per share of $[__] and the deemed offering price of $[__] per unit. This dilution would increase to the extent that the anti -dilutionprovisions of the Class B ordinary shares result in the issuance of Class A ordinary shares on a greater than one -to -onebasis upon conversion of the Class B ordinary shares at the time of our initial business combination and would become exacerbated to the extent that public shareholders seek redemptions from the trust. In addition, because of the anti -dilutionprotection in the founder shares, any equity or equity -linkedsecurities issued or deemed issued in connection with our initial business combination would be disproportionately dilutive to our Class A ordinary shares. The non-managing sponsor members have expressed an interest to purchase [__] of the units in this offering, which could reduce the trading volume, volatility and liquidity for our shares, adversely affect the trading price of our shares and, further, may present a conflict of interest for such non-managing sponsor members in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. The non -managingsponsor members have expressed to us an interest in purchasing up to an aggregate of approximately [__] units in this offering at the offering price (assuming the exercise in full of the underwriter’s over -allotmentoption), or up to [__]% of this offering. None of the non -man